1. Pink Sheet

Drug Pricing: CMS Seeing ‘Too Many Examples’ Of Excessive Increases

 
• By Cathy Kelly

Acting Administrator Slavitt says big prescription drug price increases are a widespread practice and controlling drug costs ‘is likely to be a big priority’ for next head of CMS.

The Centers for Medicare and Medicaid has become aware that the significant price increases implemented over the years by Mylan Pharmaceuticals Inc. for its EpiPen emergency allergy treatment is far from “a one-off” situation, according to Acting Administrator Andy Slavitt.

“The data tells me there’s not something highly unique about that pattern of pricing increase,” he told the BioPharma Congress...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 
• By Eliza Slawther

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By Xu Hu

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.